Systematic identification of genetic modifiers in the response to targeted therapies in acute myeloid leukemia.

Project description

Profiling cancer response to drugs

Emerging evidence suggests that anti-cancer drugs targeting oncogene-associated products often lead to resistance, impeding therapy. Given that the mechanisms of drug resistance remain elusive, the EU-funded AML-SynergyX project aims to understand how acute myeloid leukaemia (AML) cells respond to small-molecule inhibitors against common AML gene rearrangements or targets such as FLT3 and MLL. Researchers will employ genetic and transcriptome technologies to profile the primary response and adaptation of cancer cells to drug inhibition. Overall, the work will assist in the design of new drugs and the choice of combinatorial treatments for improved clinical outcome.

Fields of science

• medical and health sciences › clinical medicine › oncology › leukemia

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-EF-SE - Society and Enterprise panel

Coordinator

FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH

Net EU contribution

€ 186 167,04

Address

Campus-vienna-biocenter 1
1030 Wien
Austria

Region

Wien › Wien

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 0,00